---

---

Incyte Corporation

INCY | $53.88 0.84% 230K |

Health Technology

(0.0% 1d) (-6.8% 1m) (-28.8% 1y) (0.0% 2d) (0.0% 3d) (-2.9% 7d) (28.27% volume)
Earnings Calendar: 2024-02-13
Market Cap: $ 12,097,467,777
http://www.incyte.com
Sec Filling | Patents | 1456 employees


(US) Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Drugs

JAKAFI (ruxolitinib)
PEMAZYRE (pemigatinib)

add to watch list Paper trade email alert is off

---

Press-releases

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight
Published: 2024-04-15 (Crawled : 22:00) - prnewswire.com
INCY | $53.88 0.84% 230K |

Health Technology

| Email alert Add to watchlist
t-cell for therapy growth market

---

Incyte to Report First Quarter Financial Results - April 11, 2024
Published: 2024-04-11 (Crawled : 21:00) - biospace.com/
INCY | $53.88 0.84% 230K |

Health Technology

| -2.85% | O: 0.62% H: 1.17% C: -0.76%
first report financial results

---

CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
Published: 2024-04-01 (Crawled : 12:30) - globenewswire.com
INCY | $53.88 0.84% 230K |

Health Technology

| -6.78% | O: -0.6% H: 0.0% C: -0.58%
license collaboration asia agreement china

---

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
INCY | $53.88 0.84% 230K |

Health Technology

| -6.78% | O: -0.6% H: 0.0% C: -0.58%
license collaboration asia agreement

---

Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published: 2024-03-27 (Crawled : 00:00) - prnewswire.com
SNYNF | $92.966 630 |

Health Technology

| -7.0% | O: -0.26% H: 0.0% C: 0.0%
LLY | $745.04 -0.76% 730K |

Health Technology

| -3.11% | O: 0.49% H: 0.84% C: -0.07%
SNY | $46.2 0.59% 210K |

Health Technology

| -4.74% | O: 1.06% H: 0.0% C: 0.0%
INCY | $53.88 0.84% 230K |

Health Technology

| -5.52% | O: -0.09% H: 1.42% C: 1.1%
ibi310 first cancer colon therapy study

---

MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
NVSEF | $93.6375 82K |

Health Technology

| -4.76% | O: -0.23% H: 0.0% C: 0.0%
NVS | $93.29 -1.19% 530K |

Health Technology

| -5.37% | O: -0.07% H: 0.09% C: -0.7%
XNCR | $19.18 -4.63% 95K |

Health Technology

| -11.8% | O: -0.66% H: 4.19% C: 3.13%
MOR | $17.995 -0.14% 140K |

Health Technology

| -0.83% | O: 0.22% H: 0.22% C: -0.93%
INCY | $53.88 0.84% 230K |

Health Technology

| -9.94% | O: 0.03% H: 1.47% C: -0.72%
year update financial results

---

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
Published: 2024-03-12 (Crawled : 00:00) - prnewswire.com
SNY | $46.2 0.59% 210K |

Health Technology

| -3.03% | O: 0.01% H: 0.0% C: 0.0%
INCY | $53.88 0.84% 230K |

Health Technology

| -12.11% | O: -0.12% H: 0.3% C: -2.29%
preclinical meeting

---

Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published: 2024-03-05 (Crawled : 06:00) - prnewswire.com
SNY | $46.2 0.59% 210K |

Health Technology

| -0.28% | O: 1.17% H: 0.0% C: 0.0%
INCY | $53.88 0.84% 230K |

Health Technology

| -10.53% | O: 0.4% H: 0.38% C: -1.77%
lung cancer treatment therapeutics china

---

New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
Published: 2024-03-04 (Crawled : 14:30) - biospace.com/
INCY | $53.88 0.84% 230K |

Health Technology

| -9.52% | O: 0.34% H: 0.89% C: 0.79%
meeting growing

---

Knight Therapeutics Announces Launch of Minjuvi® in Brazil
Published: 2024-02-29 (Crawled : 12:30) - globenewswire.com
XNCR | $19.18 -4.63% 95K |

Health Technology

| -11.76% | O: 2.68% H: 2.22% C: -1.92%
INCY | $53.88 0.84% 230K |

Health Technology

| -10.92% | O: 0.38% H: 0.0% C: -3.07%
minjuvi brazil therapeutics

---

See all

---

Your Today's Watch List

Sign in to create a watchlist

---

Gainers vs Losers

50%

50%

Top 10 Gainers

TPET | $0.503 117.66% 21M |

n/a

WISA 4 | $3.22 84.0% 56M |

Electronic Technology

SXTC | $2.56 82.86% 11M |

Health Technology

PRSO | $1.99 56.69% 52M |

Manufacturing

PALI | $6.5 56.25% 22M |

Manufacturing

JAGX | $0.1767 48.74% 430M |

Health Technology

DYNT | $0.5255 41.87% 18M |

Health Technology

MCBC | $13.795 38.92% 820K |

Finance

BTTR | $6.86 34.51% 5.2M |

Manufacturing

SNGX | $0.51 32.09% 6.3M |

Health Technology

---

Last 48 Hours Insiders Buying

HNRA | $2.65 12.29% 220K |

n/a

| 15:02
TGEN | $0.67 16K |

Utilities

| 14:30
RMCF | $3.6492 3.8K |

Consumer Non-Durables

| 20:10

---

12 months watchlist earnings calendar

---